Pharmacogenetic association of diabetes-associated genetic risk score with rapid progression of coronary artery calcification following treatment with HMG-CoA-reductase inhibitors —results of the Heinz Nixdorf Recall Study

HMG-CoA-Reductase inhibitors (HMGRIs) are currently the most widely used group of drugs in patients with coronary artery disease (CAD) and are given preemptively to patients with high levels of cholesterol, including those with diabetes mellitus (DM). However, intake of HMGRIs also increases the pro...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Naunyn Schmiedebergs Arch Pharmacol
Glavni autori: Pechlivanis, Sonali, Jung, Dominik, Moebus, Susanne, Lehmann, Nils, Mahabadi, Amir A., Hoffmann, Per, Erbel, Raimund, Nöthen, Markus M., Bachmann, Hagen S.
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2021
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8298241/
https://ncbi.nlm.nih.gov/pubmed/34021798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00210-021-02100-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items